Agendia announced two partnerships that will bring its genomic testing platforms to more patients.
The Amsterdam-based company has reached a deal with Illumina to co-develop an in vitro diagnostic based on Agendia’s MamaPrint...
Minute Insight: Agendia Collaborates With Illumina And Brazilian Health Care Providers
Listen to this article
The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.
Keep up with the top medtech business and regulatory news.
More from Minute Insights
- • By
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
- • By
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
- • By
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
- • By
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
More from Medtech Insight
- • By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
- • By
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
- • By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
